MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ -- MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary ...
The University of Pennsylvania (Penn), a world-renowned academic research and medical center with a history of innovation, was announced as the first site for the COMPASS-CAD trial, a prospective ...
COMPASS-CAD started enrolling patients in November 2024 at Penn Medicine and has expanded to other sites. In COMPASS-CAD, patients classified as intermediate or borderline risk based on traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback